AlloVir (NASDAQ:ALVR) Stock Price Up 1.8% – Still a Buy?
by Kim Johansen · The Markets DailyAlloVir, Inc. (NASDAQ:ALVR – Get Free Report)’s share price was up 1.8% during trading on Thursday . The company traded as high as $3.46 and last traded at $3.40. 100,018 shares were traded during trading, an increase of 538% from the average daily volume of 15,685 shares. The stock had previously closed at $3.34.
AlloVir Stock Up 0.9%
The firm has a market cap of $17.70 million, a PE ratio of -0.17 and a beta of 0.63. The company has a 50-day simple moving average of $4.43 and a two-hundred day simple moving average of $6.56.
About AlloVir
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.